Ricevi le ultime notizie sulle azioni NRX Pharmaceuticals con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di NRXP

Ultime notizie per

NRX PHARMACEUTICALS INC

NRX Pharmaceuticals

NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

NRX Pharmaceuticals Inc

Health Care

Press Releases

General

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Expanded Access Policy for NRX-100 (preservative-free ketamine)

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller and Rockefeller Capital

UPDATE -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller, Sponsored by Rockefeller Global Family Office

News

NRx Pharmaceuticals (NASDAQ:NRXP) to Participate in a Fireside Chat at H.C. Wainwright's 27th Annual Global Investment Conference on Monday, September 8th

Management

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Complete the Acquisition of Dura Medical; Initial Acquisition in Network of Interventional Psychiatry Clinics

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx's Proposed Strength of Preservative-Free Ketamine

Penny Stocks

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Re-Files Abbreviated New Drug Application (ANDA) for KETAFREE™, Preservative-Free IV Ketamine

$750 Million Market Projected to Reach $3.35 Billion in 2034; Mega Opportunity for Superior Preservative-Free Ketamine Drug Treating Suicidal Depression: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Present at Noble Capital Markets October 2025 Emerging Growth Virtual Equity Conference

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Inclusion of Cohen & Associates, LLC of Sarasota, FL into the HOPE Network and Appointment of Dr. Rebecca Cohen as HOPE Medical Director

NRXP

Anebulo Pharmaceuticals, Inc. - Common Stock

Anebulo Pharmaceuticals

Assertio Holdings

Biote

Cumberland Pharmaceuticals Inc. - Common Stock

Cumberland

Cardiol Therapeutics Inc. - Class A Common Shares

Cardiol Therapeutics

Hyperion DeFi

ImageneBio

Intercure

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

Nasus Pharma

Nutriband

Oramed Pharmaceuticals Inc. - Common Stock

Oramed Pharmaceuticals

Pliant Therapeutics

Quantum Biopharma Ltd. - Class B Subordinate Voting Shares

Quantum BioPharma

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Hldgs

Rafael Holdings, Inc. Class B Common Stock

Rafael Holdings

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics

Reviva Pharmaceuticals Holdings, Inc. - Common Stock

Reviva Pharmaceuticals

Scilex Holding

Sol-Gel Technologies Ltd. - Ordinary Shares

Sol-Gel Technologies

Telomir Pharmaceuticals, Inc. - Common Stock

Telomir Pharmaceuticals

Talphera

Tvardi Therapeutics

Universe Pharmaceuticals Inc - Ordinary Shares

Comments

NRX Pharmaceuticals Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO